SCHEMBL3455863

SCHEMBL3455863

Nc1nc(-c2ccco2)c(-c2ccnc(NCCO)c2)c(-c2ccco2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.43
ADORA2A P29274 11/20 0.42
ADORA1 P30542 8/20 0.42
KDR P35968 2/20 0.41
CDK1 P06493 1/20 0.41
MAPK14 Q16539 2/20 0.39
ADORA2B P29275 2/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
KMT2A Q03164 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
ESR2 Q92731 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3455140 0.90 PIM1 (0.44) KARS1ADORA2AADORA1ADORA2BALDH1A1
SCHEMBL3455078 0.89 ADORA2A (0.42) ADORA2AADORA1ADORA2BADORA3PTPN7
SCHEMBL3455656 0.88 HRH3 (0.46) KARS1ADORA2AADORA1KDRCDK1
SCHEMBL3456373 0.87 TLR8 (0.47) ADORA2AADORA1KDRCDK1MAPK14
SCHEMBL3455246 0.87 HRH3 (0.42) KARS1ADORA2AADORA1KDRCDK1
SCHEMBL3455793 0.86 ADORA2A (0.43) ADORA2AADORA1ADORA2BADORA3
SCHEMBL3455266 0.83 ADORA2A (0.47) ADORA2AADORA1MAPK14ADORA2BADORA3
SCHEMBL13942285 0.82 ADORA2A (0.46) ADORA2AADORA1MAPK14ADORA2BMEN1
SCHEMBL3455897 0.79 ADORA1 (0.45) ADORA2AADORA1ADORA2B
SCHEMBL3455101 0.79 ADORA2A (0.46) ADORA2AADORA1MAPK14ADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP claimed
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1439175-A1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF CBR3, AHR, HCCS KARS1 163/4885ADORA2A 539/4885ADORA1 328/4885
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof ADORA2B, ADORA2A, ADORA3 KARS1 1726/4885ADORA2A 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.